XLXueer Li

Xueer Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xueer Li has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Xiao-Li Tian

    Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Science Nanchang University, and Jiangxi Province Key Laboratory of Aging and Disease Nanchang Jiangxi China

    3 shared publications
  • Andong Wu

    Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China

    2 shared publications
  • Xue-Ting Gong

    Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China

    2 shared publications
  • Ya Zhao

    Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China

    2 shared publications
  • Abdul Haseeb Khan

    Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Shenzhen, China

    1 shared publication
  • Bingbing Zhou

    Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China

    1 shared publication

Latest Publications

  • Open Access

    Aqueous Extract of Fructus Choerospondiatis Peel Suppresses Vascular Inflammation and Alleviates Atherosclerosis via AKT/c-FOS/IL-6 Axis

    by Andong Wu, Jiayi Dong, Jiankun Liu, Xueting Gong, Xueer Li, Bingbing Zhou, Ming Wan, Weixin Lv, Jiayu Qiu, Ya Zhao, et al.

    Background: Atherosclerosis is the pathological basis for lethal cardio-cerebral vascular diseases, such as coronary artery disease and stroke. Fructus Choerospondiatis (FC) has demonstrated cardiac protective effects in multiple ethnomedicine. Whether these protective effects are attributed to the prevention of vascular atherosclerosis, however, remains unknown. We aim to examine the anti-atherosclerotic effect of FC aqueous extract and elucidate the underlying mechanism. Methods: FC was separated into peel and pulp, and the aqueous extract was obtained separately by boiling in water to mimic decocting. Atherosclerosis model was established in ApoE−/− mice fed with a high-fat diet, and histological analysis were utilized to evaluate the development of atherosclerosis. Various inflammatory models were constructed in mice to evaluate the anti-inflammatory effect of FC extract systemically, including acute local inflammation induced by traumatic injury (ear/foot swelling), acute systemic inflammation triggered by pathogenic infection (LPS- and POLY (I:C)-induced), as well as chronic inflammatory conditions associated with oxidative stress (D-galactose-induced), metabolic disorder (db/db mice), and aging. LC-MS and network pharmacology identified bioactive components and targets. Western blotting, ELISA, qPCR, and immunofluorescence were utilized to analyze the key genes involved in the mechanisms. Results: FC peel extract reduced serum IL-6 level, atherosclerotic plaque area, and macrophage content in the plaque, while pulp extract showed no protective effects. Peel extract exhibits anti-inflammatory effects in all models. The integrative application of LC-MS and network pharmacology identified ellagic acid as the major bioactive component and AKT as its target protein. Mechanistically, FC peel extract inhibits AKT phosphorylation, suppresses c-FOS expression and nuclear translocation, reduces IL-6 transcription and inflammation, and thus alleviates atherosclerosis. Conclusions: FC peel aqueous extract exerts anti-atherosclerotic effect by inhibiting inflammation through AKT/c-FOS/IL-6 axis. This study provides novel insights into the protective effects against atherosclerosis of FC peel and highlights its potential application in the prevention and treatment of coronary artery diseases.

  • Open Access

    Nanotherapeutic Strategy via ADSC-mitoEVs Rescues Ischemic Angiogenesis through Mitophagy and Mitochondrial Metabolic Reprogramming

    by Yuan-Zheng Zhu, Min-Chen Zhang, Xue-Er Li, Xing-Hong Zeng, Xue-Ting Gong, Yu-Zi Wu, Ze-Jun Dong, Shu Wu, Xue-Fei Liu, Yang-Yan Yi

    Ischemic vascular diseases are critically associated with mitochondrial dysfunction in endothelial cells, leading to impaired angiogenesis and compromised tissue repair. Although mitochondrial transfer has emerged as a promising therapeutic strategy for revascularization, its clinical translation has been hindered by inefficient delivery systems. In this study, we show that mitochondrial-enriched extracellular vesicles derived from adipose-derived stem cells (ADSC-mitoEVs) function as an efficient nanotherapeutic, restoring angiogenic function both in vitro and in a murine model of diabetic hindlimb ischemia. Mechanistically, the uptake of ADSC-mitoEVs triggered PINK1/Parkin-mediated mitophagy in recipient endothelial cells, a process essential for initiating angiogenesis. Moreover, ADSC-mitoEVs directly delivered functional mitochondrial proteins, including superoxide dismutase 2 (SOD2), into the endogenous mitochondrial network, which enhanced antioxidant defense and improved bioenergetic capacity independently of mitophagy, as shown by reduced reactive oxygen species and elevated ATP production even in PINK1-silenced cells. Our results demonstrate ADSC-mitoEVs as a versatile, cell-free nanotherapeutic that promotes mitochondrial quality control and metabolic reprogramming, offering a potent therapeutic avenue for ischemic vascular diseases.

  • Alteration of N-glycosylation of CDON promotes H2O2-induced DNA damage in H9c2 cardiomyocytes

    by Liping Chen, Hongfei Liu, Wenxing Zhan, Changkun Long, Fang Xu, Xueer Li, Xiao-Li Tian, Shenghan Chen


  • Open Access

    Hyperglycemia Promotes Endothelial Cell Senescence through AQR/PLAU Signaling Axis

    by Yiqi Wan, Zhirui Liu, Andong Wu, Abdul Haseeb Khan, Ying Zhu, Shuangjin Ding, Xueer Li, Ya Zhao, Ximo Dai, Jin Zhou, et al.

    Hyperglycemia is reported to accelerate endothelial cell senescence that contributes to diabetic complications. The underlying mechanism, however, remains elusive. We previously demonstrated AQR as a susceptibility gene for type 2 diabetes mellitus (T2DM) and showed that it was increased in multiple tissues in models with T2DM or metabolic syndrome. This study aimed to investigate the role of AQR in hyperglycemia-induced senescence and its underlying mechanism. Here, we retrieved several datasets of the aging models and found the expression of AQR was increased by high glucose and by aging across species, including C. elegans (whole-body), rat (cardiac tissues), and monkey (blood). we validated the increased AQR expression in senescent human umbilical vein endothelial cells (HUVECs). When overexpressed, AQR promoted the endothelial cell senescence, confirmed by an increased number of cells stained with senescence-associated beta-galactosidase and upregulation of CDKN1A (P21) as well as the prohibited cellular colony formation and G2/M phase arrest. To explore the mechanism by which AQR regulated the cellular senescence, transcriptomic analyses of HUVECs with the overexpression and knockdown of the AQR were performed. We identified 52 co-expressed genes that were enriched, in the terms of plasminogen activation, innate immunity, immunity, and antiviral defense. Among co-expressed genes, PLAU was selected to evaluate its contribution to senescence for its highest strength in the enrichment of the biological process. We demonstrated that the knockdown of PLAU rescued senescence-related phenotypes, endothelial cell activation, and inflammation in models induced by AQR or TNF-α. These findings, for the first time, indicate that AQR/PLAU is a critical signaling axis in the modulation of endothelial cell senescence, revealing a novel link between hyperglycemia and vascular dysfunction. The study may have implications in the prevention of premature vascular aging associated with T2DM.